The global Intestinal Fistula Treatment Market is anticipated to attain US$46.82 billion by 2033. Compared to the value of US$26.64 billion in 2023, this indicates a notable increase and a 5.8% compound annual growth rate (CAGR) for the projection period (2023-2033).
Over the course of the forecast period, the market for intestinal fistula treatments is anticipated to expand due to a number of factors, including an increase in Crohn’s disease and ulcerative colitis prevalence as well as increased awareness of the condition worldwide. A number of prominent industrial players are devoting considerable attention to research and development alongside investigating novel and promising approaches for the management of intestinal fistulas.
Refine Strategies: Request Your Sample:
https://www.futuremarketinsights.com/reports/sample/rep-gb-16376
For instance, phase 3 clinical trials conducted by Eli Lilly and Company evaluated the long-term safety and effectiveness of mirikizumab in children and adolescents with moderate-to-severe ulcerative colitis or Crohn’s disease. It is consequently anticipated that this will quicken market expansion during the projection period.
Furthermore, the increasing need for biologics to address a range of illnesses has compelled industry players to expand their product portfolios and market their goods globally. Thus, it is also expected that in the near future, the market would expand due to rising patient preferences for prescriptions and a rise in regulatory approvals for the pharmaceuticals offered by the key companies. Increased awareness of intestinal fistula therapy and an increase in hospitalization instances for the disease are the primary factors expected to propel market expansion. An NCBI article from 2020 states that there are nine to twenty instances of ulcerative colitis for every 100,000 persons annually.
Key Takeaways from the Market Study
- Global intestinal fistula treatment market was valued at US$ 25.18 Billion by 2022-end
- From 2018 to 2022, the market demand expanded at a CAGR of 2%
- By drug class, proton-pump inhibitors to yield 45% revenue in the global intestinal fistula treatment market
- By distribution channel, the hospital pharmacies segment dominates the market with a share of 46%
- From 2023 to 2033, intestinal fistula treatment worth is expected to flourish at a CAGR of 8%.
- By 2033, the market value of Intestinal Fistula Treatment is expected to reach US$ 82 Billion
“An upsurge in financial support to researchers for developing new innovative drugs for treatment of intestinal fistula, coupled with increasing prevalence of Crohn’s disease are expected to fuel the Intestinal Fistula Treatment Market in the forthcoming years,” remarks an FMI analyst.
Competitive Landscape
- Livealth BioPharma
- Boehringer Ingelheim International GmbH
- Pfizer Inc.
- Apsolabs
- AstraZeneca
- Pipelinepharma
- Astellas Pharma Inc.
- Caspian Tamin Pharmaceutical Company
- Eli Lilly
- GlaxoSmithKline
- Bristol-Myers Squibb
- Merck & Co. KGaA
- Moderna Inc.
Recent Developments:
- In May 2021, Bristol Myers Squibb announced that the Food and Drug Administration (FDA) approved Zeposia (ozanimod) for the treatment of moderate to severe active ulcerative colitis in adults
- In September 2019, Janssen Biotech, Inc.’s product, STELARA, was approved for the treatment of moderate to severe active ulcerative colitis in the European Union
- In April 2019, Salix Pharmaceuticals entered into an exclusive license agreement with Mitsubishi Tanabe Pharma to commercialize and develop late stage investigational S1P modulator for the treatment of inflammatory bowel disease
- In October 2018, Allergan launched a personalized study approach for clinical research programs in inflammatory bowel disease. These programs would evaluate the efficacy and safety of brazikumab and the potential correlation between biomarkers and the patient outcomes with brazikumab.
Customization Available:
https://www.futuremarketinsights.com/customization-available/REP-GB-16376
Key Segments Covered in the Intestinal Fistula Treatment Industry Analysis
By Drug Class:
- Anticholinergic
- Proton-Pump Inhibitors
- H2 Blockers
- Antidiarrheals
By Route of Administration:
- Oral
- Parenteral
- Rectal
- Transdermal
- Intravenous
By Distribution Channel:
- Hospital Pharmacies
- Clinical Pharmacies
- Drug Stores
- Online Pharmacies
Obtain Detailed Market Analysis: Purchase Now to Access:
https://www.futuremarketinsights.com/checkout/16376
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
